Get started
Author

Vaia Stavropoulou

Observed names: Stavropoulou, Vaia, V Stavropoulou, V. Stavropoulou
ORCID: 0000-0002-3000-2205
Observed ORCID: 0000-0002-3000-2205
OpenAlex ID: A5027733991
MLL-AF9 Expression in Hematopoietic Stem Cells Drives a Highly Invasive AML Expressing EMT-Related Genes Linked to Poor Outcome
2016 · Vaia Stavropoulou, Susanne Kaspar, et al. · Cancer Cell · 249
PDF
Bone Marrow Mesenchymal Stem Cells Support Acute Myeloid Leukemia Bioenergetics and Enhance Antioxidant Defense and Escape from Chemotherapy
2020 · Dorian Forte, María García-Fernández, et al. · Cell Metabolism · 220
PDF
Estrogen Signaling Selectively Induces Apoptosis of Hematopoietic Progenitors and Myeloid Neoplasms without Harming Steady-State Hematopoiesis
2014 · Abel Sánchez-Aguilera, Lorena Arranz, et al. · Cell stem cell · 140
PDF
Ontogenic Changes in Hematopoietic Hierarchy Determine Pediatric Specificity and Disease Phenotype in Fusion Oncogene–Driven Myeloid Leukemia
2019 · Cécile K. Lopez, Esteve Noguera, et al. · Cancer Discovery · 61
PDF
Mitotic Infidelity and Centrosome Duplication Errors in Cells Overexpressing Tripeptidyl-Peptidase II
2005 · Vaia Stavropoulou, Jianjun Xie, et al. · Cancer Research · 59
Functional characterization of high levels of meningioma 1 as collaborating oncogene in acute leukemia
2010 · T Liu, D Jankovic, et al. · Leukemia · 38
TPPII promotes genetic instability by allowing the escape from apoptosis of cells with activated mitotic checkpoints
2006 · Vaia Stavropoulou, Vanessa Vasquez, et al. · Biochemical and Biophysical Research Communications · 32
A Novel Inducible Mouse Model of MLL‐ENL‐driven Mixed‐lineage Acute Leukemia
2018 · Vaia Stavropoulou, Marwa Almosailleakh, et al. · HemaSphere · 30
The Impact of the Cellular Origin in Acute Myeloid Leukemia: Learning From Mouse Models
2019 · James Neil Fisher, Natarajaswamy Kalleda, et al. · HemaSphere · 21
Aggressive leukemia driven by MLL-AF9
2016 · Vaia Stavropoulou, Antoine H. F. M. Peters, et al. · Molecular & Cellular Oncology · 17
PDF
The MAPK Signaling Cascade is a Central Hub in the Regulation of Cell Cycle, Apoptosis and Cytoskeleton Remodeling by Tripeptidyl-Peptidase II
2008 · Ramakrishna Sompallae, Vaia Stavropoulou, et al. · Gene Regulation and Systems Biology · 16
PDF
Tumor-localized CD40 agonism with MP0317, a FAP x CD40 DARPin, reprograms the tumor microenvironment in patients with advanced solid tumors: an open-label, nonrandomized, dose-escalation phase 1 study
2026 · Neeltje Steeghs, Carlos Gomez-Roca, et al. · Nature Cancer · 10
PDF
A phase 1b/2 study evaluating efficacy and safety of MP0250, a designed ankyrin repeat protein (DARPin) simultaneously targeting vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), in combination with bortezomib and dexamethasone, in patients with relapsed or refractory multiple myeloma
2024 · Stefan Knop, Monika Szarejko, et al. · eJHaem · 10
PDF
Viral clearance, pharmacokinetics and tolerability of ensovibep in patients with mild to moderate COVID‐19: A phase 2a, open‐label, single‐dose escalation study
2022 · Manon L. M. Prins, Johan L. van der Plas, et al. · British Journal of Clinical Pharmacology · 10
PDF
Insights into molecular pathways for targeted therapeutics in acute leukaemia
2010 · V Stavropoulou, L Brault, et al. · Swiss Medical Weekly · 10
PDF
Effect of MP0317, a FAP x CD40 DARPin, on safety profile and tumor-localized CD40 activation in a phase 1 study in patients with advanced solid tumors.
2024 · Neeltje Steeghs, Carlos A. Gomez-Roca, et al. · Journal of Clinical Oncology · 8
Ensovibep, a SARS‐CoV‐2 antiviral designed ankyrin repeat protein, is safe and well tolerated in healthy volunteers: Results of a first‐in‐human, ascending single‐dose Phase 1 study
2023 · Nina Stojcheva, Stacy Gladman, et al. · British Journal of Clinical Pharmacology · 6
PDF
Phase I study of MP0317, a FAP-dependent DARPin, for tumor-localized CD40 activation in patients with advanced solid tumors.
2023 · Carlos A. Gomez-Roca, Neeltje Steeghs, et al. · Journal of Clinical Oncology · 5
The Designed Ankyrin Repeat Protein Antiviral Ensovibep for Nonhospitalized Patients With Coronavirus Disease 2019: Results From EMPATHY, a Randomized, Placebo-Controlled Phase 2 Study
2024 · Jeff Kingsley, Nagalingeswaran Kumarasamy, et al. · Open Forum Infectious Diseases · 3
1130. Ensovibep antiviral activity in ambulatory patients with COVID-19 is independent of baseline anti-SARS-CoV-2 antibodies and exhibits minimal selective pressure – Results from the placebo-controlled EMPATHY trial
2022 · Luis Abrishamian, Marc Bonten, et al. · Open Forum Infectious Diseases · 2
PDF
612 Comprehensive biomarker analyses from a phase 1 study reveals marked tumor microenvironment modulation in patients with advanced solid tumors treated with MP0317, a FAP-localized CD40 agonistic DARPin
2024 · Jennifer Krieg, Vaia Stavropoulou, et al. · Journal for ImmunoTherapy of Cancer · 1
1475 A phase 1 study to characterize the safety and tolerability of MP0317, a tumor targeting FAP dependent CD40 agonist DARPin, in patients with relapsed/refractory solid tumors
2022 · Hilde De Winter, Elena Fernandez, et al. · Journal for ImmunoTherapy of Cancer · 1
PDF
170TiP A phase I study to characterize the safety and tolerability of MP0317, a tumor targeting FAP dependent CD40 agonist DARPin®, in patients with relapsed/refractory solid tumors
2021 · S. Jeger, O. Schönborn-Kellenberger, et al. · Annals of Oncology · 1
Phase 1/2 study of MP0533, a tetra-specific T cell engager (CD33 x CD123 x CD70 x CD3), in patients with relapsed/refractory AML or MDS/AML: Initial results from optimized treatment regimen including densified MP0533 dosing and adapted premedication
2025 · Pierre Bories, Mojca Jongen-Lavrencic, et al. · Blood
PDF
721 Ongoing phase 1 study of MP0317, a FAP-CD40 DARPin, shows a favorable safety profile and early evidence of tumor-localized CD40 activation in patients with advanced solid tumors
2023 · Carlos Gomez-Roca, Neeltje Steeghs, et al. · Journal for ImmunoTherapy of Cancer
PDF
Works count: 36
Citation count: 950
H-index: 11
I10-index: 15
Year
Topic
Type